Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1

Interventions

Gemcitabine 21Cisplatin 16durvalumab 12lenvatinib 11Oxaliplatin 11pembrolizumab 6Liver Transplantation 4Leucovorin 4Floxuridine 4tislelizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Fluorouracil 3Drug Therapy 3Capecitabine 3Biopsy 3tremelimumab 2pemigatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2apatinib 2Taxes 2Specimen Handling 2Injections 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × KP 1339 × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡